Otezla 14-Day 10/20/30 Starter Pack
RxNorm 1492748

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 1492748 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: Otezla 14-Day 10/20/30 Starter Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

PSN
Otezla 14-Day 10/20/30 Starter Pack
AUI:12888808
View
SY
Otezla 14-Day 10/20/30 Starter Pack
AUI:12888805
View
BPCK
{4 (apremilast 10 mg Oral Tablet [Otezla]) / 4 (apremilast 20 mg Oral Tablet [Otezla]) / 19 (apremilast 30 mg Oral Tablet [Otezla]) } Pack [Otezla 14-Day 10/20/30 Starter Pack]
AUI:12888910
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

PSNPrescribable

Prescribable Name (PSN):
Otezla 14-Day 10/20/30 Starter Pack
(Atom ID: 12888808)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Otezla 14-Day 10/20/30 Starter Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1492748
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12888808
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
1492748
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
SYPrescribable

Synonym (SY):
Otezla 14-Day 10/20/30 Starter Pack
(Atom ID: 12888805)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
Otezla 14-Day 10/20/30 Starter Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1492748
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12888805
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
1492748
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
BPCKPrescribable

Brand Name Pack (BPCK):
{4 (apremilast 10 mg Oral Tablet [Otezla]) / 4 (apremilast 20 mg Oral Tablet [Otezla]) / 19 (apremilast 30 mg Oral Tablet [Otezla]) } Pack [Otezla 14-Day 10/20/30 Starter Pack]
(Atom ID: 12888910)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{4 (apremilast 10 MG Oral Tablet [Otezla]) / 4 (apremilast 20 MG Oral Tablet [Otezla]) / 19 (apremilast 30 MG Oral Tablet [Otezla]) } Pack [Otezla 14-Day 10/20/30 Starter Pack]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
1492748
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12888910
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
BPCK
Brand Name Pack ({# (Ingredient Strength Dose Form) / # (Ingredient Strength Dose Form)} Pack [Brand Name])
Source Code
1492748
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Apremilast


Apremilast is used to treat psoriatic arthritis (a condition that causes joint pain and swelling and scales on the skin). It is also used to treat moderate to severe plaque psoriasis (skin disease in which red, scaly patches form on some areas of the body) in people who may benefit from medications or phototherapy (a treatment that involves exposing the skin to ultraviolet light). Apremilast is used to treat ulcers in the mouth in people with Behcet's syndrome (a disorder that causes blood vessel swelling in the body). Apremilast is in a class of medications called phosphodiesterase inhibitors. It works by blocking the action of certain natural substances in the body that cause inflammation.
[Learn More]


* Please review the disclaimer below.